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ABSTRACT 
Objective: The objective of the current research work was to prepare and evaluate novel subcutaneous sustained release polymeric nanoparticles 
for low molecular weight heparin (LMWH).  
Methods: In this study, we prepared subcutaneously administered polymeric nanoparticles encapsulating LMWH using different grades of 
polycaprolactons (PCL) (14k, 45k, 80k) and 0.1% Polyvinyl alcohol (PVA) solution as surfactant by employing water–in-oil in-water (w/o/w) 
emulsion and evaporation method. The formulated nanoparticles were evaluated for size, shape, zeta potential, in vitro drug release, and in vivo 
biological activity (anti factor Xa activity) using standard kit, antithrombotic activity in thrombosis induced rat model. Drug and polymer 
interactions in the nanoparticles were evaluated using Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD). 
Results: Scanning electron microscopic (SEM) studies on the nanoparticles confirmed the formation of spherical particles with smooth surface. The 
size of the formed nanoparticles were about 415-495 nm. The % entrapment of nanoparticles was found to be between 69-81%. Nanoparticles 
showed slow and sustained pattern of release for about 59-65 % in 48 h. Optimized nanoparticles exhibited excellent improvement in 
pharmacokinetic parameters and showed good antithrombotic activity, Activated partial thromboplastin time (aPTT) activity when compared to 
free drug. FTIR studies indicated that there was no loss in chemical integrity of the drug upon fabrication into nanoparticles. XRD results 
demonstrated that the drug changed its physical form in the formulation. 
Conclusion: The results of this study revealed that subcutaneous nanoparticles were excellent candidates for sustained drug delivery of LMWH to 
avoid repeated subcutaneous administration. 
Keywords: Low molecular weight heparin, Subcutaneous, Stability, Polycaprolactone, Venous thrombosis, Activated partial thromboplastin time 
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INTRODUCTION 
Low molecular weight heparin (LMWH) is an anticoagulant used in 
the prevention and therapy of venous thrombosis (VT). LMWH 
poorly absorbed in the gastrointestinal tract because of its large size, 
anionic charge, and enzymatic degradation and first pass 
metabolism [1,2]. So, it has to be administered via the parenteral 
(intravenous/ subcutaneous) route. LMWH requires repeated 
subcutaneous administration in 24 h duration, which is a major 
drawback in clinics [3]. Recently, various studies addressed 
subcutaneously administrated sustained release LMWH 
nanoparticles using PCL, and these studies demonstrated sustained 
release of drug for 2-10 d in vitro and in vivo [4, 5]. 
Polycaprolactone (PCL) is a biodegradable, hydrophobic polymer 
approved by the Food and Drug Administration (FDA) for a variety 
of purposes [6]. It has been used in the development of various 
control release particulate delivery systems, due to its ease of 
preparation, compatible with numerous other polymers, versatility, 
biocompatibility, commercial availability at reasonable cost. Further, 
it is a hydrophobic polymer and upon hydrolytic degradation 
produces harmless and reasonable products [6, 7]. In the present 
investigation, we chose three different molecular weight 
polycaprolactones to prepare novel LMWH nanoparticulate control 
release delivery systems for subcutaneous administration to prolong 
the release of drug in the body to avoid repeated administration. 
Nanoparticles are popular dosage forms by now used in a variety of 
therapeutic applications [8, 9]. 
Polycaprolactone-based control release systems were recently 
addressed. Yerragunta et. al., developed a 3-month drug releasing 
risperidone microspheres using blends of PCL. In this study, the 
developed formulation exhibited 90 d sustained drug release in vitro 
and in vivo. Furthermore, optimized formulation pharmacodynamics 
of the drug was measured using locomotor testing, locomotor 
activity of the optimized formulation was reduced during the study 
period when compared to the control [6]. Navitha et. al., recently 
developed 3 mo PCL based drugs-releasing implant for risperidone. 
In this study, a 12 w steadily sustained release risperidone PCL 
microsphere without a lag period was investigated using different 
molecular weight PCLs. Optimized formulation exhibited sustained 
zero-order release behaviour for 90 d without initial burst release 
and lag phase [7].  
Some attempts to develop effective subcutaneous sustained release 
dosage forms for LMWH have been reported. Pazzini et. al., [2015] 
developed subcutaneous polymeric nanoparticles encapsulating 
enoxaparin using PCL and tested in venous thrombosis rat model. 
This study exhibited good results in relation to the encapsulation 
efficiency and shown sustained release of drug for a greater period 
time about 16 h in vivo than that of free drug solution [5]. Jogala et. 
al., [2015] developed subcutaneous sustained release nanoparticles 
for LMWH using PLGA (50:50,85:15) and tested in an animal model. 
This study demonstrated good encapsulation efficiency and 
sustained drug release in vitro and in vivo for 10 d. Furthermore, 
optimized formulation exhibited a four-fold enhancement in AUC0-∞ 
compared to free enoxaparin [4]. Choubey et. al., developed 
pegylated enoxaparin (P-ENX) for subcutaneous sustained release. 
This study exhibited excellent results in relation to the 
pharmacokinetic parameters. P-ENX (pegylated enoxaparin) has 
shown about three-fold enhancement in half life and four-fold 
enhancement in AUC in comparison to the pure enoxaparin [10]. 
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In this study, our goal was to develop novel subcutaneous sustained 
release nanoparticles for LMWH and to evaluate various in vitro, in 
vivo parameters such as pharmacokinetic parameters, activated 
partial thromboplastin time, thrombotic activity in venous 
thrombosis rat model. Further, the drug properties in optimized 
formulations were determined and the results are discussed 
MATERIALS AND METHODS 
Materials 
LMWH (Enoxaparin) was a gift sample from Gland Pharma Pvt. 
Ltd.(Hyderabad, India). PCL (14k.45k, 80k) were purchased from 
Sigma-Aldrich Ltd., Germany. Dichloromethane and polyvinyl 
alcohol were purchased from SD Fine chemicals Ltd. A UV-Visible 
spectrophotometer from Thermo scientific was used. Probe 
sonicator (Qsonica. USA), Cooling centrifuge (Hittech, MIKRO 220R, 
Germany), Freeze dryer, Mini Lyodel (Delvac pumps, Chennai India) 
were used for the formulation of Nanoparticles. A JSM-5200 
Scanning Electron microscope (SEM) Japan, was used to study the 
surface morphology of Nanoparticles. Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK) was used to measure the particle size and 
zeta potential of prepared nanoparticles. Fourier transforms 
infrared spectrophotometer (FTIR) from Perkin-Elmer and X-ray 
diffractometer (XRD) from PAN Analytical were used. All other 
ingredients used in this study were of analytical grade 
Methods 
Preparation of nanoparticles 
The LMWH nanoparticles were prepared by the water–in-oil in-
water (w/o/w) emulsion and evaporation method. The required 
quantity of drug was taken in 2 ml of PVA solution (1%). To this 10 
ml of methylene chloride containing the polymer (PCL 14000, PCL 
45000, PCL 80000) was added and emulsified with a probe 
sonicator (Sonica) for 30 s at 60W. The resulting w/o emulsion was 
then poured into 40 ml of PVA (0.1%) solution and sonicated for 60 
s at 60W using probe sonicator involving in the formation of w/o/w 
emulsion. This emulsion was kept on a magnetic stirrer (15 rpm) for 
10 min to evaporate methylene chloride. Nanoparticles were then 
isolated by centrifugation (Hittich, MIKRO 220R), at 18000 rpm for 
15 min.[11,12] The supernatant was removed and assayed to find 
out entrapment efficiency. The nanoparticles were washed three 
times with deionized water and subjected to freeze drying 
(Lyophilizer, MINI–LYODELDELVAC, Chennai, India). 
Size and surface analysis 
The mean diameter of nanoparticles and their surface potential were 
evaluated with Zeta sizer. Surface morphology was evaluated using 
scanning electron microscopy (SEM).  
Scanning electron microscopy 
In order to examine the particle surface morphology and shape, 
scanning electron microscopy (SEM) was used. A concentrated 
aqueous suspension was spread over a slab and dried under vacuum. 
The sample was shadowed in a cathodic evaporator with gold layer 20 
nm thick. Photographs were taken using a JSM-5200 Scanning 
Electron Microscope (Tokyo, Japan) operated at 20 KV. The smallest 
size nanosuspension was used for determining surface morphology.  
Zeta potential 
The zeta potential is used to measure the electric charge on the 
surface of the particles, indicating the physical stability of colloidal 
systems. In this study, the zeta potential was assessed by 
determining the electrophoretic mobility of the particles. The zeta 
potential was measured using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK). Samples were diluted with the 
respective original dispersion medium which provides information 
regarding the thickness of the diffuse layer. Diluted nanosuspension 
was added to the sample cell (quartz cuvette) and was put into the 
sample holder unit, and zeta potential was measured.  
Encapsulation efficiency 
The amount of drug entrapped in nanoparticles was determined by 
turbidimetric assay by measuring the amount of non-entrapped 
drug in the supernatant recovered after centrifugation. Briefly, 1 ml 
of supernatant was taken to this 1 ml of acetate buffer (1M, pH 5) 
followed by 4 ml of cetyl pyridinium solution (0.1%) in Nacl 0.94% and 
assayed for drug release at 500 nm by UV spectrophotometer [13]. 
In vitro drug release 
An aliquot of 10 mg of nanoparticles was suspended in a flask 
containing 25 ml of phosphate buffer saline (PBS 0.011M, Nacl 
0.15M, pH7.4), and kept it for stirring (150 rpm) on a magnetic 
stirrer. 1 ml of sample was taken at 1,3,6,9,12,18,24,30,36 and 48 h 
using a syringe filter. To this 1 ml of acetate buffer (1m pH 5) 
followed by 4 ml of cetyl pyridinium solution (0.1%) in Nacl 0.94% 
were added and the drug was assayed at 500 nm by UV 
spectrophotometer [11, 13]. 
Selection and characterization of optimized formulation 
Using size, zeta potential, encapsulation, in vitro drug release, the 
optimum formulation was selected. The optimized formulation was 
characterized for various properties. 
In vivo drug release from LMWH nanoparticles 
The in vivo biological activity of LMWH was evaluated by measuring 
the anti-factor Xa activity with a chromogenic substrate by using a 
standard kit (KRIBIOLISA™ Xa) from Krishgen Biosystems according 
to the method described by the supplier. In vivo biological activity of 
LMWH was investigated in male Wistar rats. All the experiments 
were conducted according to the guidelines of CPCSEA (Committee 
for the Purpose of Control and Supervision on Experimental 
Animals. The study was approved by an animal ethical committee of 
Synapse Life Sciences; Warangal registered under CPCSEA, India. 
The animals were divided into 2 groups(n=6). The groups are as 
below:  
Group 1: Subcutaneous administration of PNP2 formulation  
Group 2: Subcutaneous administration of LMWH solution 
Group 1 received 0.3 ml suspension of PNP2 formulation 
subcutaneously. Group 2 received 0.3 ml suspension LMWH 
solution. All the formulations administered had equal amounts of 
LMWH. After administration of formulations blood samples were 
collected at 6, 12,18, 24 h and 2,3,4,5,6,7,8,9,and 10 d and the 
samples were subjected to centrifugation for 10 min at 5000g, using 
centrifuge (REMI RM 12C), then the plasma collected and anti-factor 
Xa activity was measured using a standard kit (KRIBIOLISA™ Xa) 
from Krishgen Biosystems according to the method described by the 
supplier [4, 14, 15]. 
Antithrombotic activity in animal model of venous thrombosis  
The rats were divided into 3 groups (n=6) with an average weight of 
the rats was 250g. All the rats were anesthetized by intraperitoneal 
injection of a solution of ketamine (0.15 ml), xylazine (0.5 ml) and 
deionized water (0.75 ml) in does a dose of 0.2 ml for 100 g of 
weight. From the in vitro evaluation, PNP2 formulation was selected 
as optimized formulation. A 4.5 mg/kg of PNP2 formulation was 
injected subcutaneously to one group; a second group was injected 
with 4.5 mg/kg LMWH solution, and the third group was injected 
with normal saline solution subcutaneously. One hour after the 
administration, the abdomen of the animals was surgically opened, 
and thrombosis was induced according to the modified method 
[11,16]. Three hours after thrombosis induction, animals were 
anaesthetised, and the abdomen reopened to verify the presence of 
thrombus. If thrombus was present, it was withdrawn and weighed 
immediately and after drying for 24 h at 37 °C. 
Estimation of activated partial thromboplastin time (aPTT) 
Blood coagulation-indicating parameter, namely activated partial 
thromboplastin time, was measured in male Wister rats. All the 
experiments were conducted according to the guidelines of CPCSEA 
(Committee for the Purpose of Control and Supervision on 
Experimental Animals). The study was approved by an animal 
ethical committee of Synapse Life Sciences; Warangal registered 
under CPCSEA, India. The animals were divided into2 groups (n=5). 
The day before the experiments, all the rats were cannulated from 
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right jugular vein according to a standard procedure using a 
polyethylene catheter connected to a silicone rubber tubing. For 
complete recovery from anesthesia and surgery, the animals were 
then kept individually overnight in a temperature-controlled room 
with a 12-h light–dark daily cycle. During this period, the animals 
were kept in standard cages with free access to rat chow and water. 
On the day of experiments, group 1 and group 2 of the rats received a 
200 IU/kg dose of free heparin and the equal dose of drug-loaded 
nanoparticles, respectively, via the catheter.  At the time just before 
the drug administration (time 0), and also at 1,3,6,12,18,24,30,26,42, 
and 48 h following the heparin doses, 0.5-ml blood samples were 
obtained via the catheters and were mixed immediately with 
trisodium citrate 3.2% (0.109 M) with a volume ratio of 9: 1 (blood: 
sodium citrate) before centrifuging for 15 min at 1500 g to obtain 
plasma. 100 µl of plasma was taken in a cuvette and pre–warmed to 37 
°C. Then, 100 µl of the aPTT-XL reagent was added onto the plasma, 
and the mixture was incubated for 4 min at 37 °C. At the end of 4 min, 
100 ml of pre-warmed calcium chloride solution (0.02 M) was added 
to the plasma-reagent mixture, and clot formation was timed [11, 17]. 
Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectrum of drug, polymers, physical mixture and 
formulations were obtained on FTIR instrument. Sample about 2 
mg was mixed thoroughly with 100 mg potassium bromide IR 
powder and compacted under vacuum at a pressure of about 12 
Psi for 3 min. The resulting disc was mounted in a suitable holder 
in Shimadzu IR spectrophotometer, and the spectrum was scanned 
over the wave number range of 4000-400 cm-1. IR helps to confirm 
the identity of the drug and to detect the interaction of the drug 
with the carriers. 
Powder X-ray diffractometry (PXRD) 
The XRD patterns of Drug, PEG, polymer, physical mixture and 
optimized formulation were obtained using X-ray diffractometer 
(Shimadzu 770). The measuring conditions were as follows: Cu Kα, 
radiation, nickel filtered; graphite monochromator; 40 KV voltage; 
and 30 mA current with X’celerator detector. All samples were run 
at 1 ° (2θ) min-from 3 ° to 45 ° (2θ). 
 
Table 1: Composition of various polymeric nanoparticle (PNP) formulations 
Ingredients PNP1 PNP2 PNP3 
LMWH (mg) 20 20 20 
PCL 14000 (mg) 100 --- --- 
PCL 45000 (mg) --- 100 ---- 
PCL 80000 (mg) --- --- 100 
Dichloromethane (ml) 10 10 10 
PVA solution (0.1%) (ml) 40 40 40 
Water (ml) 2 2 2 
 
RESULTS AND DISCUSSION 
Low molecular weight heparin is the drug of choice for various 
diseases where its anticoagulant activity useful. Further, it has an 
insignificant oral bioavailability, short half life and needs to repeat 
subcutaneous administration [11]. In the present investigation, for 
the first time, we fabricated polymeric subcutaneous sustained 
release nanoparticles encapsulating LMWH using polycaprolactones 
of different molecular weights. Nanoparticles were successfully 
prepared by water-in-oil-water (w/o/w) emulsion and evaporation 
method. Three formulations were prepared using different grades of 
PCL (14k, 45k, 80k) and 0.1% PVA as a surfactant.  
Poly caprolactone (PCL) is a type of synthetic, FDA-approved 
biodegradable polymer; FDA approved applying in food packaging, 
tissue engineering, drug delivery, So it becomes one of the most 
promising biodegradable polymers currently available on the market. 
PCL have gained enormous prominence because of its practical and 
market viable drug delivery applications. It is also in the search for 
appropriate matrices for control drug delivery microspheres and 
nanoparticles, because of its commercial availability at reasonable 
cost, ease of preparation, biocompatibility, versatility and its 
hydrolytic degradation products are resorbable, harm-less [7]. 
However, some shortcomings such as low melting temperature and 
low mechanical properties restrict widespread use of PCL. 
Recently Pazzini et. al., developed subcutaneous polymeric 
nanoparticles of enoxaparin using PCL and tested in venous 
thrombosis rat model. This study has shown good encapsulation 
efficiency (80%) and demonstrated sustained release of enoxaparin 
from encapsulated nanoparticles for a greater period of time (16 h) 
in vivo than that of free enoxaparin. Furthermore encapsulated 
enoxaparin nanoparticles demonstrated excellent antithrombotic 
activity in venous thrombosis rat model [5]. Recently Navitha et. al., 
and Yerragunta et. al., developed control drug release risperidone 
implants, microspheres respectively. Wang et. al., developed 
Disodium nor canthari date loaded PCL microspheres by W/O/W 
emulsion solvent evaporation, this study demonstrated good results 
in relation to particle size and encapsulation efficiency, initial burst 
release followed by sustained release of drug from microspheres 
[18]. Chawala et. al., developed PCL based tamoxifen nanoparticles 
for tumour-targeted delivery. This study demonstrated the 
formation of spherical shape and uniform size (250-300 nm) 
nanoparticles. Furthermore, fabricated nanoparticles demonstrated 
good encapsulation efficiency (64%). 
In the present study, the particle size of the all the nanoparticle 
formulations was found between 415-495 nm. The study of SEM was 
conducted to confirm the formation and surface morphology of 
nanoparticles. All the nanoparticles were spherical in shape with a 
smooth surface. These were shown in fig. 1. The nanoparticles 
exhibited negative surface charges; this negative charge increases 
the stability of prepared nanoparticles by minimizing the 
agglomeration of nanoparticles, the negative charge of the particles 
due to the presence of low molecular weight heparin, surfactant, and 
the polymers. Here PVA works as particle stabilizer and increases 
the stability of nanoparticles probably due to steric stabilization 
phenomena [5, 11]. The Encapsulation efficiency of the prepared 
particles was determined by turbidimetric assay method. 
Encapsulation efficiencies of the nanoparticles PNP1, PNP2, PNP3 
are 71±0.31, 81±0.25, 69±0.25 respectively. The maximum 
encapsulation efficiency (81±0.25) was exhibited by PNP2 
nanoparticles. PCL 25 k is a hydrophobic polymer, even though it 
exhibited good encapsulation efficiency, a recent study reported the 
similar results by using PCL 45K [5]. Thus, this method of 
preparation is suitable for encapsulation of hydrophilic drugs in 
polymeric nanoparticles. The results of particle size, encapsulation 
efficiency, zeta potential are depicted in table 2. 
 
 
Fig. 1: Scanning electron microscope pictures of the 
nanoparticles
Jogala et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 6, 264-268 
267 
Table 2: Particle size, zeta potential and encapsulation efficiencies of all nanoparticle formulations 
Formulation  Particle size (nm) Zeta potential (mv) Encapsulation efficiency (%) 
 PNP1 415±1.21 -17.4±0.8 71±0.31 
PNP2 425±2.12 -23.5±0.6 81±0.25 
PNP3 495±3.35 -26.1±0.7 69±0.25 
The values indicates n=3, mean±SD 
 
In vitro drug release of the, all the three formulations were 
performed in 25 ml of phosphate buffer saline (PBS 0.011M, Nacl 
0.15M, PH7.4) as per the method described above. The release 
profiles are shown in fig. 2. All the formulations sustained the 
release of the drug for a period of 48 h. PNP2 formulation exhibited 
slow and sustained release pattern and maximum drug release is 
about 65.25% in 48 h. This is must be due to the hydrophilic nature 
and its high crystallinity of the polymer (PCL). High crystallinity in 
the particles can lead to slow rate of drug release in the sustained 
pattern. From the results of in vitro evaluation of the nanoparticles, 




Fig. 2: In vitro drug release profiles of all the formulations 
(n=6,mean±SD) 
 
In vivo drug release studies were performed for optimized (PNP2) 
formulation and pure drug solution. Plasma concentration vs time 
profile of the PNP2 formulation and pure drug solution was depicted 
in fig. 3. PNP2 nanoparticles and the low molecular weight heparin 
solution were administered subcutaneously to the rat, and the blood 
samples were withdrawn, and plasma was collected at different time 
intervals and then anti-factor xa activity was measured PNP2 
formulation exhibited excellent results when compared to the free 
drug solution. For pure drug solution peak plasma concentration 
(Cmax) was 14.9 µg/ml, Tmax was 1h, AUC0-∞ was 40.452 (µg/ml/h) 
and after 6 h concentration was 0.2 µg/ml. PNP2 formulation 
exhibited prolonged plasma concentration for 24 h. Peak plasma 
concentration (Cmax) was 13.9 µg/ml,and, Tmax was 12 h, AUC0-∞ was 
141.25 (µg/ml/h) After 24 h concentration of drug in plasma was 
about 3.2 µg/ml. Optimized formulation exhibited 3.5 times 
enhancement(40.452 vs 141.25 µg/ml/h) in area under curve (AUC0-
∞). This is must be due to the hydrophobic nature of the polymer. 
Antithrombotic activity of the optimized formulation (PNP2) and the 
pure drug solution, control (normal saline solution) determined in 
venous thrombosis induced rat model. The weight of the thrombi 
formed after subcutaneous administration of control, pure drug 
solution, and optimized formulation was to be 22.10±0.13, 
4.4±0.21,0.71±0.1 mg respectively. 
The weight of the thrombi formed in the group of rats which 
received the optimized formulation was very less when compared to 
the weight of the thrombi formed in the groups of rats which 
received the pure drug solution and normal saline solution. This is 
probably due to the maintenance of the minimum of the 
concentration of the drug (0.26 µg/ml) in the plasma for a prolonged 
period of time which requires for the venous prevention thrombosis. 
The results were represented in fig. 4. 
 
Fig. 3: Plasma concentration profiles of optimized formulation 




Fig. 4: Weight of thrombus after subcutaneous administration 
of control, free drug, and Optimized formulation (PNP2).  
(n=6, mean±SD) 
 
Activated partial thromboplastin time (aPTT) for pure drug solution 
and optimized (PNP2) formulation was estimated after 
subcutaneous administration. For free drug solution aPTT increased 
rapidly with average maximal aPTT of about 162 s occurred at 1 h. 
After subcutaneous of PNP2 formulation maximum aPTT of about 
102 s occurred about in 18 h. aPTT of both free drug and optimized 
formulation increased from starting time of about 18 s to final value 
(162 s for a free drug, 102 s for optimized formulation). The free 
drug reached maximal aPTT very early, but the optimized 
formulation reached about in 10 h. 
FTIR spectra of the drug, polymers and optimized formulation were 
recorded in the range of 4000-400 cm-. The FTIR spectra of drug and 
PCL 45k compared with the FTIR spectra of the optimized 
formulation. The characteristic functional groups of drug and PCL 
45k showed peaks in the following wavenumber. In pure drug there 
was C-O stretching at 1230 cm-, N-H stretching at 3350 cm-, N-H 
bending at 1624 cm-. S=O peak at 1145 cm-. In PCL 45K 
characteristic broad peak of O-H was there at 3500-3600 cm-. C-H 
stretching sharp peak at 2850 cm-. There was the appearance of 
same characteristic peaks are appeared in the optimized 
formulation this indicates there was no chemical interaction 
between drug and polymers used (data not shown). The presence of 
peaks in the expected range confirms that the materials taken for the 
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study are genuine, and there was no occurrence of possible 
interactions. XRPD study yielded interesting results. The drug was 
crystalline due to the sharp peaks demonstrated in XRPD. With the 
optimized nanoparticles, there was a small bump in the peak, 
suggesting partial conversion of LMWH to less crystalline form and 
that may be due to the formation of amorphous form upon 










In conclusion, in this investigation, we formulated novel and better 
subcutaneous sustained release nanoparticles for low molecular 
weight heparin (LMWH), optimized the formulation so as to 
demonstrate excellent results in relation to the particle size, 
encapsulation efficiency (81%) and in vitro sustained drug release 
for 48 h with about 65% drug release. Optimized formulation 
demonstrated 3.5-folds enhancement AUC when compared to a free 
drug solution. Furthermore, optimized formulation demonstrated 
excellent antithrombotic activity in venous thrombosis rat model. 
Based on the above results, these fabricated nanoparticles would 
serve as a promising prospect for the efficient prevention of venous 
thrombosis. The results were tempting for the clinical realization of 
the formulation and can be taken forward for further development.  
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